Skip to main content
Erschienen in: Reactions Weekly 1/2024

01.03.2024 | Case report

Elexacaftor/ivacaftor/tezacaftor

Rebound effect in the form of worsening of cystic fibrosis following compassionate use and exposure during first trimester of pregnancy

Erschienen in: Reactions Weekly | Ausgabe 1/2024

Einloggen, um Zugang zu erhalten

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literatur
Zurück zum Zitat Cimino G, et al. Use of elexacaftor/tezacaftor/ivacaftor combination in pregnancy. Archives of Gynecology and Obstetrics 309 : 9-15, Mar 2023. Available from: URL: https://dx.doi.org/10.1007/s00404-023-06962-5 Cimino G, et al. Use of elexacaftor/tezacaftor/ivacaftor combination in pregnancy. Archives of Gynecology and Obstetrics 309 : 9-15, Mar 2023. Available from: URL: https://dx.doi.org/10.1007/s00404-023-06962-5
Metadaten
Titel
Elexacaftor/ivacaftor/tezacaftor
Rebound effect in the form of worsening of cystic fibrosis following compassionate use and exposure during first trimester of pregnancy
Publikationsdatum
01.03.2024
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2024
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-024-53757-y

Weitere Artikel der Ausgabe 1/2024

Reactions Weekly 1/2024 Zur Ausgabe

Case report

Nivolumab

Case report

Dupilumab

Case report

Obinutuzumab

Case report

COVID-19-vaccine